Abstract

This study is to determine peak 5HT1 a receptor occupancy of CP-361, 428 in the brain using the PET ligand WAY-100635. To determine 5HT1 a receptor occupancy of CP-361, 428 in the brain at approximately 25% of peak concentrations using the PET ligand WAY-100635. A D4 specific PET ligand is not available to measure the affinity of CP-361, 428 in the brain; thus the investigator will use the PET ligand carbonyl 11-WAY 100635 to measure 5HT1 a receptors in the brain. This is reasonable because CP-361, 428 has similar affinity for D4 and 5HT1 a receptors. The dose selected (10mg) will be administered for 7 days to mimic steady state concentrations and will provide information about the likely effectivene3ss of this dose for future studies. The third PET scan will take place 24 hours after the last dose of CP-361, 428 and is timed to provide receptor occupancy similar to a 2.5 mg dose at steady state, another dose that may be valuable in future studies.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR001066-23
Application #
6409687
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1978-02-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
23
Fiscal Year
2000
Total Cost
Indirect Cost

  Institution

Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199

  Publications

Gidding, Samuel S; Bacha, Fida; Bjornstad, Petter et al. (2018) Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr 192:86-92.e5
Srinivasa, Suman; Lu, Michael T; Fitch, Kathleen V et al. (2018) Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antivir Ther 23:1-9
Schorr, Melanie; Dichtel, Laura E; Gerweck, Anu V et al. (2018) Sex differences in body composition and association with cardiometabolic risk. Biol Sex Differ 9:28
Srinivasan, Shylaja; Kaur, Varinderpal; Chamarthi, Bindu et al. (2018) TCF7L2 Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). Diabetes Care 41:554-561
Kelsey, Megan M; Braffett, Barbara H; Geffner, Mitchell E et al. (2018) Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. J Clin Endocrinol Metab 103:2309-2318
Kleinberger, Jeffrey W; Copeland, Kenneth C; Gandica, Rachelle G et al. (2018) Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med 20:583-590
Fourman, Lindsay T; Czerwonka, Natalia; Shaikh, Sofia D et al. (2018) Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV. AIDS 32:927-932
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2018) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes 19:191-198
Arslanian, Silva; El Ghormli, Laure; Kim, Joon Young et al. (2018) The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in ?-Cell Function in TODAY. Diabetes Care :
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44

Showing the most recent 10 out of 945 publications